In draft guidance , published today (10 September 2010), NICE has asked Bristol-Myers Squibb and Otsuka Pharmaceuticals to provide more data on the effectiveness of their product, aripiprazole (Abilify), as a treatment for schizophrenia in people aged 15 to 17 years. This draft guidance has been issued for consultation and the manufacturer now has an opportunity to respond to the independent Appraisal Committee's considerations and requests...
Read from Source
|
